Dr. Wang Weiping (second from left, front row) and his research team. Mr. Long Kaiqi (first from left, front row) was the co-first author of the article.
Researchers at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and collaborators from the School of Basic Medical Sciences, Fudan University, Shanghai, have developed an ‘intravenous injection plus light-triggered intraocular drug release’ strategy to achieve drug accumulation in retinoblastoma. The strategy avoids invasive intravitreal drug administration and shows promise in treating retinoblastoma and other eye diseases. The research has just been published in Advanced Science [link to publication], and a Patent Cooperation Treaty (PCT) patent application has been filed based on this work.
Source:
Li Ka Shing Faculty of Medicine, The University of Hong Kong
Date: August 30, 2021
Topic: HKUMed achieves a breakthrough in retinoblastoma treatment by a light-triggered drug release system
Link: https://www.med.hku.hk/en/news/press/20210830-rb-treatment-by-light-triggered-drug-release-system
Relevant information can also be found in the following articles:
幫新創
Date: September 1, 2021
Topic: 視網膜母細胞瘤新療法 光照觸發奈米藥物於腫瘤集結釋放
星島⽇報
Date: August 31, 2021
Topic: 港大研新藥治視網膜母細胞瘤
頭條⽇報
Date: August 31, 2021
Topic: 港大研新藥治視網膜母細胞瘤
中國基建報
Date: August 31, 2021
Topic: 香港大學取得視網膜母細胞瘤治療新突破
AM730
Date: August 30, 2021
Topic: 港大研發光照觸發釋藥系統 治療視網膜母細胞瘤新突破